Experts

At the heart of K-CONNECT PLATFORM lies a distinguished group of oncology experts and researchers from across the region. These respected panelists and advisory board members serve as the guiding force behind the platform, offering invaluable insights, real-world case studies, and strategic direction. Their collective expertise helps shape the future of precision and personalized oncology.

As we prepare for K-CONNECT APAC 2025 in Da Nang, Vietnam, we proudly introduce the thought leaders who are driving this mission forward.

Medical Oncology

(12 Experts)

Surgical Oncology

(12 Experts)

Clinical Oncology

(12 Experts)

Geneticists

(12 Experts)

Medical Oncology

Professor

Nick Pavlakis

University of Sydney, Australia

Associate Professor

Sita Laksmi Andarini

National Referral for Repiratory diseases, RSUP Persahabatan

Doctor

Samuel Haryono

Siloam MRCCC, Jakarta, Indonesia

Professor

Mai Trong Khoa

Vice President, Vietnam Immunotherapies Association

Associate Professor

Le Thuong Vu

University Medical Center, Ho Chi Minh City

Associate Professor

Nguyen Thi Minh Phuong

Hong Ngoc Hospital - Phuc Truong Minh

Doctor

Rattiya Cheewakriangkrai

Chiangmai Ram Hospital, Thailand

Associate Professor

Sutima Luangdilok

Chulalongkorn University, Thailand

Professor

Pornchai O-Charoenrat 

Chaophya Hospital, Thailand

Doctor

Maria Belle Francia

St. Lukes BGC

Doctor

Au Siu Kie

President of Hong Kong Precision Oncology Society, Hong Kong

Professor

Aya El Helali

Center of Cancer Medicine, The University of Hong Kong

Professor

Feng-Ming (Spring) Kong

The University of Hong Kong

Medical Lead (Oncology division)

Nguyen Duy Sinh

Gene Solutions

Principal Investigator

Tu Ngoc Ly Lan

Gene Solutions

Contact Us

© 2025 GENE SOLUTIONS. All rights reserved.

The K-CONNECT Platform creates as a collaborative initiative that brings together leading oncologists and researchers from across the region. The platform serves as a bridge between cutting-edge technology and expert practitioners, aiming to unlock the potential of ctDNA-MRD for precision and personalized oncology.